1. Home
  2. MATV vs DCTH Comparison

MATV vs DCTH Comparison

Compare MATV & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mativ Holdings Inc.

MATV

Mativ Holdings Inc.

HOLD

Current Price

$7.97

Market Cap

440.9M

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$12.64

Market Cap

372.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATV
DCTH
Founded
1995
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
440.9M
372.5M
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
MATV
DCTH
Price
$7.97
$12.64
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$22.00
AVG Volume (30 Days)
472.3K
444.0K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
4.24%
N/A
EPS Growth
N/A
107.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.97
$24.54
Revenue Next Year
$4.20
$33.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.17
$8.12
52 Week High
$15.48
$13.74

Technical Indicators

Market Signals
Indicator
MATV
DCTH
Relative Strength Index (RSI) 51.58 51.50
Support Level $7.89 $10.10
Resistance Level $8.32 $13.74
Average True Range (ATR) 0.37 0.55
MACD 0.08 -0.10
Stochastic Oscillator 67.67 22.54

Price Performance

Historical Comparison
MATV
DCTH

About MATV Mativ Holdings Inc.

Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: